Topical treatment of basal cell carcinoma with the immune response modifier imiquimod

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

(2017) M. Trakatelli et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Immunocryosurgery for Non-superficial Basal Cell Carcinoma: A Pro­spective, Open-label Phase III Study for Tumours ≤ 2 cm in Diameter

(2014) G Gaitanis et al.   ACTA DERMATO-VENEREOLOGICA

Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC

(2013) K.M. McKay et al.   BRITISH JOURNAL OF DERMATOLOGY

Molecularly targeted therapies for nonmelanoma skin cancers

(2013) Lucinda S. Liu et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation

(2013) F Wolff et al.   ONCOGENE

Aldara activates TLR7-independent immune defence

(2013) Anne Walter et al.   Nature Communications

Basal cell carcinoma — molecular biology and potential new therapies

(2012) Maria Kasper et al.   JOURNAL OF CLINICAL INVESTIGATION

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

(2012) Erika Vacchelli et al.   OncoImmunology

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system

(2011) Abbi L Engel et al.   Expert Review of Clinical Pharmacology

Guidelines for the management of basal cell carcinoma

(2008) N.R. Telfer et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical investigations of Toll-like receptor agonists

(2008) Thomas Meyer et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Short German guidelines: Basal cell carcinoma

(2008) Axel Hauschild et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT